MedTrace Logo

Single Pill to Avert Cardiovascular Events

NCT01313702 · Status: WITHDRAWN · Phase: PHASE3 · Type: INTERVENTIONAL

Last updated 2022-09-21

No results posted yet for this study

Summary

The purpose of this study is to determine whether a polipill improved the compliance with treatment compared to usual care that use two or more drugs,in patients at high cardiovascular risk or previous cardiovascular disease.

Conditions

Interventions

DRUG

polipillV1

polipill version 1: aspirin 75mg, simvastatin 40mg, lisinopril 10mg, atenolol 50mg

DRUG

polipillV2

Polipill version 2: aspirin 75mg, simvastatin 40mg, lisinopril 10mg, hydrochlorothiazide 12.5mg.

DRUG

usual care

the drugs used in clinical practice, defined by physician

Sponsors & Collaborators

  • Hospital do Coracao

    lead OTHER

Principal Investigators

  • Otavio Berwanger, PhD · Instituto de Ensino e Pesquisa - IEP - HCor

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-10-31
Primary Completion
2014-04-30
Completion
2014-07-31

Countries

  • Brazil

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01313702 on ClinicalTrials.gov